Premier Alternatives

Vanqua Bio

Chicago, IL · Founded 2019 · Privately Held (backing)

Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. Vanqua Bio is based in Chicago, IL and was founded in 2019. Its last known valuation is $270 million. It has raised $149 million across 2 recorded rounds; the latest was a $45 million early-stage round in Feb 2024.

Last price · $/share
—
Implied valuation
$270.0M
Total raised
$149.0M
Last round
Early Stage VC
Feb 2024

Vanqua Bio key facts

  • Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases.
  • Vanqua Bio’s last known valuation is $270.0M.
  • It has raised $149.0M across 2 recorded rounds; the latest was Early Stage VC ($45.0M) in Feb 2024.
  • Notable investors include OrbiMed, Osage University Partners, Casdin Capital, Logos Capital, Omega Funds — 12 tracked in total.
  • Vanqua Bio has filed 2 Form Ds with the SEC since 2021, most recently Jul 2024 ($45.0M sold to 12 investors).
  • Status: Privately Held (backing).
Free account
More of Vanqua Bio with a free account
  • ·The complete investor list: 12 names
  • ·Watch Vanqua Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Vanqua Bio funding rounds

2 rounds
Feb 2024Early Stage VC$45.0MSEC filing▮
Aug 2021Later Stage VC$85.0MSEC filing▮
Full funding history →

Vanqua Bio valuation

Vanqua Bio's last known valuation is $270 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Vanqua Bio raised?

Vanqua Bio has raised $149 million across 2 recorded rounds since 2021. The largest was an $85 million later-stage round in Aug 2021; the most recent was a $45 million early-stage round in Feb 2024.

Vanqua Bio has filed 2 Form Ds with the SEC since 2021, most recently in Jul 2024 ($45 million sold to 12 investors).

Vanqua Bio investors

12 investors are on record for Vanqua Bio, including OrbiMed, Osage University Partners, Casdin Capital and Logos Capital. By type, the record holds 2 venture capital firms, 2 hedge funds and 1 private equity firm. The early-stage round in Feb 2024 drew 12 investors.

About Vanqua Bio

Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advancing programs targeting the innate immune system, which can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.

Sector
Healthcare
HQ
Chicago, IL, United States
Founded
2019
Employees
34
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$270.0M

Vanqua Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.